Division of Gynecology, National Cancer Center Hospital, Tokyo, Japan.
Gynecol Obstet Invest. 2012;73(1):26-31. doi: 10.1159/000329319. Epub 2011 Aug 26.
BACKGROUND/AIMS: To determine the clinicopathological characteristics and potentially associated outcomes in patients diagnosed with serous adenocarcinoma of the uterine cervix.
The records of surgically-treated patients with pathological stage pT1b-2b serous adenocarcinoma were reviewed.
Of 12 patients with serous adenocarcinoma who underwent radical hysterectomy, five had pT1b1N0 disease, two pT1b1N1, two pT1b2N0, and three pT2bN1. The 5-year overall survival rate for patients with or without parametrial involvement (pT2b vs. pT1b) was 0 and 89%, respectively. The 3-year recurrence-free survival rate for those with or without parametrial involvement was 33 and 89%, respectively. Four patients suffered recurrence, namely one of those who had pT1b (1/9, 11%) and 3 of those who had pT2b disease (100%). The sites of recurrence of pT2b disease were outside the pelvis in all 3 patients. Of these, 2 (67%) had peritoneal spread and 1 distant node metastasis.
While patients with pathological stage pT1b disease may have a relatively favorable outcome after radical surgery, those with more advanced disease have a poor prognosis because of extra-pelvic recurrence.
背景/目的:确定诊断为子宫颈浆液性腺癌患者的临床病理特征及可能相关的结局。
回顾接受根治性子宫切除术治疗的经病理分期为 pT1b-2b 期浆液性腺癌患者的病历记录。
12 例接受根治性子宫切除术的浆液性腺癌患者中,5 例为 pT1b1N0 期,2 例为 pT1b1N1 期,2 例为 pT1b2N0 期,3 例为 pT2bN1 期。有或无宫旁浸润(pT2b 与 pT1b)的患者 5 年总生存率分别为 0%和 89%。有或无宫旁浸润的患者 3 年无复发生存率分别为 33%和 89%。4 例患者发生复发,其中 1 例为 pT1b 期(1/9,11%),3 例为 pT2b 期(100%)。pT2b 期疾病复发的部位均在骨盆外,其中 3 例均有腹膜播散,1 例有远处淋巴结转移。
虽然病理分期为 pT1b 期的患者在接受根治性手术后可能有相对较好的预后,但疾病更晚期的患者由于盆外复发,预后较差。